drugset / Trial / NCT01967225

Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections

NCT01967225

Phase 3 Completed 125 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).

Timeline

Start
2013-11-23
Primary completion
2016-10-28
Completion
2016-10-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linezolid Other / unclassified 600 mg Intravenous
Subject Tedizolid Small molecule 200 mg Intravenous

Indications